Appili Therapeutics raises C$177,500 in first tranche of private placement

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) closed the first tranche of a non-brokered private placement, raising gross proceeds of C$177,500, the Halifax-based biopharmaceutical company announced.

The company issued 7,100,000 units at C$0.025 per unit. Each unit consists of one Class A common share and one-half of a common share purchase warrant. The warrants allow holders to purchase one common share at C$0.05 per share for 36 months from the closing date, subject to shareholder approval.

The warrants require approval from shareholders at the company's next Annual General Meeting, excluding votes from warrant holders. If approval is not obtained, the warrants will not be exercisable, according to Toronto Stock Exchange requirements.

Appili plans to use the net proceeds primarily for working capital and to fund development of certain product candidates. The company paid finders C$14,200 and issued 568,000 broker warrants in connection with the closing.

The broker warrants entitle holders to purchase common shares at a minimum price of C$0.02834 per share for 24 months from the closing date, also subject to shareholder approval under the same conditions as the regular warrants.

The company plans to close a second tranche of the private placement in December 2025. All securities issued are subject to a four-month and one-day statutory hold period from the issuance date.

Appili Therapeutics develops drugs for infectious diseases and biodefense applications. The company's pipeline includes an FDA-approved metronidazole suspension for antimicrobial resistant infections, a tularemia vaccine candidate, and a topical treatment for cutaneous leishmaniasis.

You May Also Be Interested In

• Amtech Systems closes $60 million public stock offering
• Huron acquires RelateCare to expand healthcare managed services
• Arch Capital prices $2 billion senior notes offering